coagulation factor II, thrombin
Senast uppdaterad 14 Jan 2025
Uppfyller patientens redaktionella riktlinjer
- Ladda nerLadda ner
- Dela
- Language
- Diskussion
- Ask Patient
- Ljudversion
- Lägg till i föredragna källor på Google
The F2 gene provides instructions for making a protein called prothrombin (also known as coagulation factor II). Coagulation factors are a group of related proteins that are essential for normal blood clotting (hemostasis). After an injury, clots protect the body by sealing off damaged blood vessels and preventing further blood loss.
Videoval för GenesVideobibliotek
Normal function
The F2 gene provides instructions for making a protein called prothrombin (also known as coagulation factor II). Coagulation factors are a group of related proteins that are essential for normal blood clotting (hemostasis). After an injury, clots protect the body by sealing off damaged blood vessels and preventing further blood loss.
Prothrombin is made chiefly by cells in the liver. The protein circulates in the bloodstream in an inactive form until an injury damages blood vessels. In response to the injury, prothrombin is converted to its active form, thrombin. Thrombin then converts a protein called fibrinogen into fibrin, the primary protein that makes up blood clots.
Thrombin is also thought to be involved in cell growth and division (proliferation), tissue repair, and the formation of new blood vessels (angiogenesis).
Conditions referring to this gene or chromosome
Other names
coagulation factor II
coagulation factor II (thrombin)
PT
RPRGL2
THPH1
Related patient information and medicines

Patient information leaflet
Trombofili
The body has a natural clotting process in the blood, which is altered in thrombophilia. What is thrombophilia. Thrombophilia refers to a group of conditions where the blood clots more easily than normal. This can lead to unwanted blood clots (called thromboses) forming within blood vessels. Prothrombin 20210 Prothrombin is a clotting factor, and.

Patient information leaflet
Antikoagulantia
Dabigatran Dabigatran , apixaban Apixaban tablets , edoxaban Edoxaban tablets and rivaroxaban Rivaroxaban tablets prevent a blood chemical called thrombin from working. These activated platelets and the damaged tissue release chemicals which react with other chemicals and proteins i... There are 13 known clotting factors which are called by their.

Patient information leaflet
Antifosfolipidsyndrom
It is a disease that affects the blood and makes it more likely to clot than normal - a thrombophilia. Antiphospholipid syndrome (APS) - also called Hughes' syndrome - makes blood more likely than normal to clot (a thrombophilia Thrombophilia ). This increases the risk of developing blood clots (called thromboses) within blood vessels. APS can.

Patient information leaflet
Blodproppstester
Blodproppstester are used to diagnose and assess blödning problems and to monitor people who take warfarin or other antikoagulant medicines. You may be advised to have blood clotting tests: If you have a suspected bleeding disorder. For example, if you bleed a lot after cuts, or if you bruise easily. If you have certain liver diseases that can.

Patient information leaflet
Stroke
Funktionsnedsättning following a stroke depends on factors such as the part of the hjärnans affected, how quickly treatment was given and the extent of the damage to the brain. Forn more information on strokes, go to [/health/stroke-leaflet](https://patient.info/health/stroke-leaflet) Ett stroke means that the blood supply to a part of the.

Patient information leaflet
Högar
Piles (haemorrhoids) are swollen lumps in or around the bottom that cause discomfort, itching, or bleeding. Some external piles kan strangulate (called thrombosed piles), meaning they develop a blood clot within them, causing pain, swelling, and sometimes bleeding. Infrared coagulation/photocoagulation This method of piles treatment uses infrared.
Vidare läsning och referenser
- coagulation factor II, thrombin; MedlinePlus, National Library of Medicine.
- Akhavan S, Mannucci PM, Lak M, Mancuso G, Mazzucconi MG, Rocino A, Jenkins PV, Perkins SJ. Identification and three-dimensional structural analysis of nine novel mutations in patients with prothrombin deficiency. Thromb Haemost. 2000 Dec;84(6):989-97.
- Danckwardt S, Hartmann K, Gehring NH, Hentze MW, Kulozik AE. 3' end processing of the prothrombin mRNA in thrombophilia. Acta Haematol. 2006;115(3-4):192-7. doi: 10.1159/000090934.
- Jayandharan G, Viswabandya A, Baidya S, Nair SC, Shaji RV, Chandy M, Srivastava A. Molecular genetics of hereditary prothrombin deficiency in Indian patients: identification of a novel Ala362 --> Thr (Prothrombin Vellore 1) mutation. J Thromb Haemost. 2005 Jul;3(7):1446-53. doi: 10.1111/j.1538-7836.2005.01402.x.
- Kujovich JL. Prothrombin Thrombophilia. 2006 Jul 25 [updated 2021 Feb 4]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1148/
- McGlennen RC, Key NS. Clinical and laboratory management of the prothrombin G20210A mutation. Arch Pathol Lab Med. 2002 Nov;126(11):1319-25. doi: 10.5858/2002-126-1319-CALMOT.
- Spector EB, Grody WW, Matteson CJ, Palomaki GE, Bellissimo DB, Wolff DJ, Bradley LA, Prior TW, Feldman G, Popovich BW, Watson MS, Richards CS. Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G >A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories. Genet Med. 2005 Jul-Aug;7(6):444-53. doi: 10.1097/01.gim.0000172641.57755.3a.
- Sun WY, Witte DP, Degen JL, Colbert MC, Burkart MC, Holmback K, Xiao Q, Bugge TH, Degen SJ. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7597-602. doi: 10.1073/pnas.95.13.7597.
- Varga EA, Moll S. Cardiology patient pages. Prothrombin 20210 mutation (factor II mutation). Circulation. 2004 Jul 20;110(3):e15-8. doi: 10.1161/01.CIR.0000135582.53444.87. No abstract available.
Artikelhistorik
Artikeln finns också på Engelska, Tyska, Spanska, Franska, Italienska, Portugisiska, Hindi, Hebreiska, Arabiska, och Svenska.
14 Jan 2025 | Senaste versionen
1 Jan 2025 | Ursprungligen publicerad
Dela dina tankar eller erfarenheter med andra i vår patientgemenskaper.
Anmäl dig till Patientens nyhetsbrev
Din veckovisa dos av tydliga, pålitliga hälsoråd - skrivna för att hjälpa dig känna dig informerad, självsäker och i kontroll.
Genom att prenumerera accepterar du våra Sekretesspolicy. Du kan avsluta prenumerationen när som helst. Vi säljer aldrig dina uppgifter.

